RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy
Ying Shi(Tongji University), Carol A. Pollock(The University of Sydney)
Cited by 43
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609